The latest -Companion Biomarkers in Drug Development -Report By Aarkstore

FOR IMMEDIATE RELEASE
(Free-Press-Release.com) January 25, 2012 -- Companion Biomarkers in Drug Development
http://www.aarkstore.com/reports/Companion-Biomarkers-in-Drug-Development-13521.html

The term “companion biomarker” means that a particular diagnostic test is specifically linked to a therapeutic drug either in drug development or in the clinic. Biomarkers of disease have long played an important role in diagnostic medicine as evidenced by the intense use of specific clinical laboratory tests in the diagnosis of disease. Biomarkers can be used in five very distinct ways in drug development: 1) companion biomarkers can be correlated with biological events during drug development in order to validate drug targets or to predict drug response; 2) biomarkers can be used as companion diagnostics in drug development to characterize patient populations in order to better understand the extent to which new drugs reach intended therapeutic targets can alter proposed therapeutic pathways and achieve successful clinical outcomes; 3) biomarkers can be used to stratify patient populations for drug response in primary prevention or disease-modification studies, particularly in specific clinical areas such as neuron degeneration and cancer; 4) clinically useful biomarkers are becoming increasingly useful to make proper therapeutic decisions regarding candidate drugs; and 5) clinically useful biomarkers are becoming increasingly required by the FDA and other outside authorities to make proper regulatory decisions regarding candidate drugs. This TriMark Publications report describes new biomarker technology platforms developed for the analyses of drug targets that are connected to the effectiveness of therapeutic agents in a clinical setting. The emphasis is on those companies that are actively developing and marketing new companion diagnostic tests for performing biomarker tests during drug development, as opposed to the more routine and clinically accepted companion markers that are manufactured and marketed by large diagnostic companies for routine clinical use.
Table of Contents :
1. Overview 13
1.1 Statement of Report 13
1.2 About This Report 13
1.3 Scope of the Report 13
1.4 Objectives 13
1.5 Methodology 15
2. Introduction: Companion Diagnostics in Drug Development 19
2.1 Companion Diagnostics as Biomarkers 20
2.1.1 Potential Benefits of Biomarkers as Companion Diagnostics 22
2.2 Biomarkers in Different Phases of Drug Development 22
2.2.1 Drug Discovery and Development Process 22
3. Biomarker Development Tools 66
3.1 New Technologies in Functional Genomics 66

3.1.1 Genomics-Derived Drug Pipeline 66
3.1.2 Future of Genomics Technologies for Drug Target Identification 66
3.2 Overview of Microarrays 67
4. Market for Biomarkers in Drug Development 119
4.1 C-KIT (CD117) Expression 122
4.2 CCR5 -Chemokine C-C Motif Receptor 122
Related Reports:
Companion Diagnostics in Personalized Medicine and Cancer Therapy
Cytology and HPV Testing World Markets
Diabetes, Metabolic Syndrome and Cardiovascular Disease
For Related reports Plz Follow the Link:

http://www.aarkstore.com/search/viewresults.asp?search=Biomarkers in Drug &PubId=&pagenum=1
From: Aarkstore Enterprise
Contact: Marketing Team
Mob.No.918149852585/919272852585
Email: enquiry@aarkstore.com
URL: http://www.aarkstore.com/
http://in.linkedin.com/in/aarkstore
http://www.facebook.com/aarkstore

Aarkstore Enterprise     Biomarkers     company reports     drug development